Login to get immediate access to this content.
LoginSpeaker: Michel P. Ducreux, France
Abstract discussed:
- 3O - PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase 2 study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC) - Watch the session from ESMO Gastrointestinal Cancers Congress 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published July 2024